SWOG clinical trial number
E2197

Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer

Closed
Phase
Published
Abbreviated Title
Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer
Activated
11/01/1998
Closed
01/21/2000

Research committees

Breast Cancer

Other Clinical Trials

CTSU-A012301
SWOG Clinical Trial Number

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
S2206
SWOG Clinical Trial Number

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
21% Accrual
Accrual
21%
Open
Phase
S2212
SWOG Clinical Trial Number

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)
Breast Cancer
Activated
07/21/2023
31% Accrual
Accrual
31%
Open
Phase